(NASDAQ: GNLN) has entered the battle against dangerous drugs, but not only against opioids. Greenlane announced this week its plans to launch an all-new line of fentanyl, xylazine and drink spike ...
Earlier efforts to develop non-opioid painkillers for acute pain applications have revolved mainly around nerve growth factor inhibitors, but the two leaders in the category, Eli Lilly and ...
According to Fact , "The global opioid overdose treatment market is expected to reach a value of US$ 1.54 billion in 2024, as revealed in a new industry analysis published by proficient researchers at ...